2023-11-27 07:49:39 ET
DENVER, Colo., Nov 27, 2023 ( www.247marketnews.com )- Redhill Biopharma Ltd (NASDAQ: RDHL) stated, this morning, that the U.S. Food and Drug Administration granted the Company five years’ market exclusivity for Talicia3 under the Generating Antibiotic Incentives Now (GAIN) Act Qualified Infectious Disease Product (QIDP) designation, as recommended by the FDA Exclusivity Board. This grant is on top of three years’ exclusivity granted for the approval of Talicia under section 505(b)(2). Talicia is protected by its broad intellectual property suite to 2034.
Redhill Biopharma is trading at 0.59, up $0.275 (+87.00%), on 6.36M premarket shares.
Redhill Biopharma’s 52-week range is $0.257 to $16.00. If trading volume can strengthen, it may chew through its mid-October trading resistance and begin to challenge …
The post FDA Grant News could Drive this Stock to a Double or More appeared first on 24/7 Market News .
For further details see:
FDA Grant News could Drive this Stock to a Double or More
Disclaimer
This article is for the purposes of solicitation subscriptions for this website. This website expects to generate new advertisement revenue resulting from the distribution of this article. The amount of which is unknown at this time. This website or it’s authors do not own any shares of Redhill Biopharma Ltd. (RDHL) and does not buy, sell, or trade any shares of (RDHL). This article does not provide a professional analysis of a (RDHL) financial position. (RDHL) financial position and all other information regarding the featured Company should be verified directly with (RDHL). Please read our full disclaimer for more detailed information.
